Immuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2 infection (PASC)

INTRODUCTION

As the number of patients who recover from acute coronavirus disease 19 (COVID-19) rises, it is increasingly apparent that a substantial subset displays persistent subjective and objective respiratory ailments. Patients report a high prevalence of lingering respiratory symptoms such as fatigue and dyspnea (1-4), and spirometry and diffusion capacity testing show impaired pulmonary function (3). However, little is known about the biological drivers of long-term respiratory disease after COVID-19, and how acute COVID illness severity impacts the emerging COVID-19 long-hauler syndrome, or post-acute sequelae of SARS-CoV-2 infection (PASC). To better understand the relationship between subjective and objective respiratory abnormalities and underlying biological drivers, we measured symptom burden, pulmonary function tests, and plasma biomarkers in subjects that have recovered from COVID-19 infection.

RESULTS

We enrolled 61 subjects into the post-COVID-19 clinics. Subject demographics for each group are shown in the Table. Median (IQR) age was 53 (43-62) years and sex distribution was equitable: 56% males and 44% females. Median (IQR) time from onset of COVID-19 infection to post-COVID follow up was 9 (6-11) weeks, but was not significantly different between the three COVID-19 groups. Thirteen subjects (21%) recovered at home (“home” group), 30 subjects (48%) were hospitalized but did not require ICU (“non-ICU” group) and nineteen subjects (31%) were hospitalized and required ICU level care (“ICU” group). Eight of the subjects admitted to the ICU required intubation and mechanical ventilation, but none required tracheostomy. The demographics and characteristics of the subgroup of subjects that underwent plasma biomarker testing are also shown.

Fifty-three subjects (85%) reported lingering symptoms of COVID-19, the most common being dyspnea (69%), cough (58%), fever (47%), fatigue (29%), chest pain (26%), and headache (23%) (Figure 1A). There were no significant differences in symptom burden between the home, non-ICU, and ICU groups (P=NS, Figure 1B). Pulmonary function testing was performed on 59 subjects. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity for carbon monoxide (DLCO) decreased as severity of COVID-19 increased (Figure 2A). There was no relationship between pulmonary function and presence of persistent respiratory symptoms, measured by the sum of the scores for fatigue, dyspnea, and cough (Figure 2B).

• Download figure
• Open in new tab

Figure 1: Post-COVID-19 symptom burden.

A) Prevalence of symptoms reported by subjects (n=61) at the time of initial follow up visit. B) Symptom scores (total number of symptoms reported) with median bars and interquartile range error bars for home (n=13), non-ICU (n=30), and ICU (n=18) groups. There were no significant differences between groups using the Kruskal-Wallis test with Benjamini-Hochberg post-hoc test.

• Download figure
• Open in new tab

Figure 2: Pulmonary function tests and Respiratory Symptom Score.

A) Scatter plots show forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity for carbon monoxide (DLCO) as percentages of predicted values for each subject in the home, non-ICU, and ICU groups for N (number) shown. B) Scatter plots show the sum of respiratory symptoms (1 point each for dyspnea, cough, and fatigue) vs. FVC, FEV1, and DLCO. Bars are medians and error bars are interquartile range. Statistical analysis by Kruskal-Wallis test with Benjamini-Hochberg post-hoc test. *P<0.05, **P<0.01, ***P<0.001.

To identify potential biological factors that associate with impaired pulmonary function after COVID-19 infection, we measured levels of circulating inflammatory, metabolic, angiogenic, and fibrotic markers in plasma from a subset of 22 subjects (home group n=7, non-ICU group n=5, ICU group n=10) and performed partial least-squares discriminant analysis (PLS-DA) (Figure 3). The score plot (Figure 3A) shows that subjects largely cluster in distinct quadrants based on how severe their COVID-19 illness was, even ∼9 weeks after infection. In fact, the clustering shows a counter-clockwise rotation around the origin as severity of viral infection increases from home to non-ICU to ICU-level of care. The loadings plot (Figure 3B) shows the associations between the clusters of subjects and the measured plasma biomarkers (Supplemental Table). The top right quadrant shows the biomarkers that directly correlate with critical COVID-19 illness requiring ICU admission. Several of the most impactful biomarkers (i.e. furthest from the point of origin) that associate with ICU level of care are LCN2 (lipocalin-2), MMP-7 (matrix metalloproteinase-7), and HGF (hepatocyte growth factor). Plasma levels of all three factors were similar between the control and home groups, but increased with COVID-19 severity, and were significantly higher in the ICU group (Figure 4A).

• Download figure
• Open in new tab

Figure 3: Partial least-squares discriminant analysis (PLS-DA).

A) The score plot shows each individual subject in the home (blue circles), non-ICU (purple circles), and ICU (red circles) groups. The grey zone in the score plot depicts outliers with 95% confidence. B) The loadings plot depicts associations between clusters and the measured biomarkers.

• Download figure
• Open in new tab

Figure 4: Biomarkers.

A) Plasma levels of LCN2 (lipocalin-2), MMP-7 (matrix metalloproteinase-7), and HGF (hepatocyte growth factor) in individual subjects (black circles) in the control (Ctrl), home, non-ICU, and ICU groups. Bars are means and error bars are standard deviation. Statistical analysis by one-way ANOVA with Fisher’s LSD post-hoc test. *P<0.05, **P<0.01, ***P<0.001. B). Scatter plots for subjects (black circles) of LCN2 (lipocalin-2), MMP-7 (matrix metalloproteinase-7), and HGF (hepatocyte growth factor) on abscissa versus FVC (forced vital capacity) or DLCO (diffusing capacity) on ordinate. Statistical analysis is simple linear regression. Blue shaded area shows 95% confidence intervals.

To further determine if specific circulating factors are associated with persistently impaired pulmonary function, we used random-forest feature selection (5) to identify which factors best explain the variability seen in FVC and DLCO (Supplemental Figures 1-2). This analysis identified MMP-7 as the marker that was most significantly associated with FVC and DLCO. LCN2, HGF, and leptin, among others, were also significantly associated with FVC, DLCO, or both. In our patient cohort, leptin did not differ by acute COVID-19 severity, but was strongly inversely correlated with post-COVID-19 FVC and also directly correlated with body mass index (Supplemental Figure 3). However, after adjusting for body mass index, the relationship between leptin and FVC was no longer significant. Confirmation of the relationship between LCN2, MMP-7, and HGF and pulmonary function using simple linear regression identified a highly significant, inverse correlation with FVC and DLCO (Figure 4B and 4C). There was no relationship between these three biomarkers and burden of subjective symptoms.

To validate these three biomarkers, we measured them in a separate group of 53 subjects (“validation cohort”) (Table and Supplemental Figure 4A). The validation cohort consisted of n=13 subjects in the home group, n=31 subjects in the hospitalized, non-ICU group, and n=9 subjects in the ICU group. Demographics of the discovery and validation cohorts were comparable (Table). Plasma levels of LCN2 and MMP-7 were significantly higher in the validation ICU group compared with the validation home group, whereas a statistical trend was observed for HGF (Supplemental Figure 4A). However, like the discovery cohort, all three biomarkers were highly linearly correlated with decline in FVC and DLCO (Supplemental Figures 4B and 4C).

DISCUSSION

Herein we report that among patients returning for follow-up visits for persistent symptoms after their acute COVID-19 illness, respiratory symptoms and impaired lung function are common after acute COVID-19 infection. Pulmonary function in particular worsens as COVID-19 illness severity increases. We further show that plasma biomarker profiles measured at 9 weeks after COVID-19 infection reveal prior COVID-19 severity and cluster patients accurately. Plasma LCN-2, MMP-7, and HGF levels are highest in survivors of severe COVID-19 infection and correlate strongly with pulmonary function impairment.

Patients recovering from acute COVID-19 infection commonly display persistent symptoms such as fatigue and dyspnea (1-4). Our study found a high degree of symptom burden across subgroups (home, non-ICU, ICU) that did not associate by COVID-19 severity (3). Impaired pulmonary function was reported by Huang et al (1), and similar to our findings, correlated with prior COVID-19 severity. Together these data highlight the discordance of subjective and objective respiratory abnormalities after COVID-19 infection (3), a well-known phenomenon in cardiopulmonary diseases in general (6), and indicate that subjective symptoms alone cannot discern degree of post-COVID-19 lung function impairment.

Partial least-squares discriminant analysis could reliably identify and separate subjects by COVID-19 illness severity based on their plasma biomarker profiles, even 9 weeks after recovery. Our analysis highlighted a number of important biomarkers that strongly associated with severe/ICU COVID-19 status. We chose to further analyze three of these markers, LCN2, MMP-7, and HGF based on their differing roles in host response. While these markers were similar between the healthy controls and the home group, there was a stepwise increase seen as COVID-19 severity increased. Furthermore, LCN2, MMP-7, and HGF were not associated with subjective symptoms in this study, or reported elsewhere to associate with subjective symptoms, but were strongly associated with objective respiratory function. These findings are confirmed by the validation cohort, which also found strong linear relationships between plasma biomarker levels and decline in respiratory function. LCN2 is a component of neutrophil secondary granules that was found to strongly associate with acute COVID-19 critical illness and mortality (7-10); however, the role in post-COVID-19 recovery has not been previously described. That higher levels of LCN-2 are found at 9 weeks after severe COVID-19 illness compared with non-severe cases suggests these patients may have ongoing neutrophil activation that could be amenable to targeted therapy.

MMP-7 is a protease that breaks down extracellular matrix deposited in the lung after injury. The role of MMP-7 in COVID-19 has not been reported; however, previous studies of non-COVID-19 acute lung injury have shown higher circulating levels of MMPs (11) that associate with worse disease severity and clinical outcomes (12). MMP-7 is also a validated biomarker for idiopathic pulmonary fibrosis severity that correlates with pulmonary function (13), and our findings suggest MMP-7 may be a novel biomarker of COVID-19 ARDS recovery.

HGF is a growth factor secreted by alveolar fibroblasts shown to be elevated in bronchoalveolar lavage fluid of patients with ARDS (14) and in plasma of patients with acute COVID-19 illness (15); however, the plasma levels after COVID-19 recovery have not been previously reported. In vivo and in vitro studies indicate HGF promotes alveolar epithelial and endothelial repair after acute lung injury (16, 17) via induction of counter inflammatory and anti-oxidant gene expression (18-20). Our findings suggest high HGF levels at 9 weeks post-COVID-19 could indicate ongoing alveolar repair proportionate to the degree of acute lung injury; however, further studies are needed to determine the impact of HGF on COVID-19 recovery.

Leptin is a hormone secreted by adipocytes in proportion to obesity, a risk factor for severe acute COVID-19 (21), and may contribute to immune dysregulation during acute COVID-19 (22, 23). In our patient population with post-COVID-19 syndrome, we found leptin was inversely related to FVC, however, after adjusting for body mass index, the relationship was no longer significant, indicating body mass index was a confounder. Future studies should take body mass index into account when reporting leptin results.

Our study has several limitations. First, we only recruited subjects that had ongoing symptoms after COVID-19 infection, therefore we cannot report the true prevalence of symptoms or pulmonary function derangements in subjects with asymptomatic infection or in subjects with symptom resolution after COVID-19 infection. Second, our plasma biomarker profiles represent a single time point for each subject, and therefore we cannot draw conclusions about trajectory or changes over time. Third, we cannot establish mechanism in this human cohort study; however, our findings are highly associational and lay the foundations to drive further work in this area. Fourth, the PLS-DA model was at risk for being over-fit, however this was mitigated with similar findings of the Boruta algorithm, and addressed with the addition of the validation cohort which confirmed the findings of the discovery cohort. Lastly, the majority of the patients were assessed at 9 weeks after their acute COVID-19 infection, which may not provide sufficient insights into the long term lung repair that is likely to occur beyond this timeframe. Future studies evaluating biomarker profiles and pulmonary function at later time points will provide greater insights into persistent symptoms associated with COVID-19 illness.

In conclusion, persistent respiratory symptoms and impaired lung function are common after acute COVID-19 illness, but subjective symptoms alone do not predict lung injury. Partial least-squares discriminant analysis reliably identifies and separates subjects by COVID-19 illness severity based on their plasma biomarker profiles, even 9 weeks after recovery. Circulating factors associated with acute neutrophil activation, fibrosis signaling, and alveolar epithelial repair remain elevated in survivors of acute COVID-19 infection and strongly associate with impaired pulmonary function. Our study provides novel insights into divergent host responses of lung repair after COVID-19 pneumonia and suggest that immunologic and fibrotic drivers of disease severity in the acute COVID-19 illness may regulate the trajectory of recovery in the post-COVID-19 phase. These markers may represent key prognostic tools that can be followed during and after COVID-19 illness, and may identify COVID-19 survivors at increased risk for chronic parenchymal lung disease, and will require validation in a larger study.

METHODS

AUTHOR CONTRIBUTIONS

H.J.C. and B.D.K. wrote the manuscript that was approved by all authors. All authors participated in data collection, analysis, and/or interpretation. The overall study design was conceived by Y.J.C., B.D.K., L.G.Q., A.I.L., and P.J.L.